 |
|
Aspirin–Angiotensin-Converting Enzyme Inhibitor Coadministration and Mortality in Patients With Heart Failure
A Dose-Related Adverse Effect of Aspirin
Marco Guazzi, MD, PhD;
Roberto Brambilla, MD;
Giuseppe Rèina, PhD;
Gabriele Tumminello, MD;
Maurizio D. Guazzi, MD, PhD
Arch Intern Med. 2003;163:1574-1579.
Background It is debated whether in patients with chronic heart failure (CHF), aspirin may contrast the clinical benefits of angiotensin-converting enzyme inhibitors (ACEIs). Two major unresolved issues in patients with CHF are whether these agents together can affect mortality and whether the interaction is related with the dose of aspirin. We aimed at exploring these possibilities.
Methods We evaluated more than 4000 hospitalizations with a principal discharge diagnosis of CHF from January 10, 1990, to December 31, 1999. The final analysis was restricted to 344 patients taking ACEIs who satisfied the selection criteria, in whom reliable information was available concerning drug therapy during follow-up. In these patients, treatment included no aspirin in 235 (group 1), a low dose ( 160 mg) in 45 (group 2), and a high dose ( 325 mg) in 64 (group 3).
Results During a mean follow-up of 37.6 months, there were 84 (36%) deaths in group 1, 15 (33%) in group 2, and 35 (55%) in group 3. By the Kaplan-Meier approach, survival was similar in groups 1 and 2, and significantly (P = .009) worse in group 3 compared with groups 1 and 2. After adjusting for potential confounding factors (including treatment, cause of heart disease, age, smoking, and diabetes mellitus), a time-dependent multivariate Cox proportional hazards regression analysis showed that the combination of high-dose aspirin with an ACEI was independently associated with the risk of death (hazard ratio, 1.03; P = .01) and that the combination of low-dose aspirin with an ACEI was not (hazard ratio, 1.02; P = .18).
Conclusion These results support the possibility that in some patients with CHF who are taking an ACEI, a dose-related effect of aspirin may adversely affect survival.
From the Istituto di Cardiologia (Drs M. Guazzi, Brambilla, Tumminello, and M. D. Guazzi) and Instituto di Statistica e Biometria (Dr Rèina), Università degli Studi di Milano, Milano, Italy. The authors have no relevant financial interest in this article.
THIS ARTICLE HAS BEEN CITED BY OTHER ARTICLES
|
Potential Drug Interactions and Duplicate Prescriptions Among Cancer Patients
Riechelmann et al.
JNCI J Natl Cancer Inst 2007;99:592-600.
ABSTRACT
| FULL TEXT
Response to Letter Regarding Article, "Aspirin Use and Outcomes in a Community-Based Cohort of 7352 Patients Discharged After First Hospitalization for Heart Failure"
McAlister et al.
Circulation 2007;115:e55-e55.
FULL TEXT
Platelets and heart failure
Chung and Lip
Eur Heart J 2006;27:2623-2631.
ABSTRACT
| FULL TEXT
Does Aspirin Reduce the Benefit of an Angiotensin-Converting Enzyme Inhibitor?: Choosing Between the Scylla of Observational Studies and the Charybdis of Subgroup Analysis
Jhund and McMurray
Circulation 2006;113:2566-2568.
FULL TEXT
Aspirin Use in Older Patients With Heart Failure and Coronary Artery Disease: National Prescription Patterns and Relationship With Outcomes
Masoudi et al.
J Am Coll Cardiol 2005;46:955-962.
ABSTRACT
| FULL TEXT
JournalScan
Malik
Heart 2003;89:1373-1374.
FULL TEXT
|
